Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Michael Leland

Nurse Practitioner, Family Murfreesboro, TN Nurse Practitioner

NPI 1356896955 CMS profile 10601517

1970 Medical Center Pkwy Ste K, Murfreesboro, TN 37129

Open in the dashboard

General payments

$8,760

393 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Leland of Murfreesboro, TN is reported in the CMS Open Payments database as having received $8,760 across 393 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,718 141
2024 General $1,854 71
2023 General $2,040 75
2022 General $1,116 51
2021 General $1,033 55

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Leland
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Michael Leland were reported at $2,718. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Michael Leland Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,033 $124 $35–$379 $132
2022 $1,116 $141 $44–$430 $149
2023 $2,040 $154 $49–$476 $160
2024 $1,854 $165 $51–$504 $164
2025 $2,718 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $2,078 56 payments
  2. GlaxoSmithKline, LLC. $1,027 74 payments
  3. CSL Behring $991 38 payments
  4. Pfizer Inc. $564 31 payments
  5. Novartis Pharmaceuticals Corporation $438 18 payments
  6. Genzyme Corporation $435 21 payments
  7. Regeneron Healthcare Solutions, Inc. $419 18 payments
  8. LEO Pharma Inc. $325 14 payments
  9. Genentech USA, Inc. $300 14 payments
  10. Amgen Inc. $298 21 payments
  11. Other $1,884 88 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,629 389 payments
  2. Education $86 2 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $45 2 payments
Products named General payments · program years 2021–2025
  1. TRELEGY ELLIPTA $816 64 payments
  2. TEZSPIRE $757 23 payments
  3. FASENRA $720 20 payments
  4. Haegarda $605 24 payments
  5. DUPIXENT $547 27 payments
  6. AIRSUPRA $502 7 payments
  7. Hizentra $386 14 payments
  8. CUTAQUIG $343 20 payments
  9. PANZYGA $322 19 payments
  10. AREXVY $302 12 payments
  11. Other $4,351 217 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

1,085

Median for Nurse Practitioner: 389

Drug cost

$188,226

Median for Nurse Practitioner: $21,885

Branded share of claims

35.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 137 $96,148
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 60 $39,422
Breo Ellipta Fluticasone/Vilanterol Brand 18 $13,586
Epinephrine Generic 65 $11,156
Spiriva Respimat Tiotropium Bromide Brand 11 $6,423
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 25 $4,621
Arnuity Ellipta Fluticasone Furoate Brand 15 $3,635
Montelukast Sodium Generic 215 $2,373
Azelastine Hcl Generic 81 $2,372
Albuterol Sulfate Hfa Albuterol Sulfate Brand 103 $2,071

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$25,504

Medicare's payments for the services billed

Medicare patients

231

Average age 72

Services billed

3,267

154 women, 77 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Diabetes 34%
Ischemic heart disease 26%
Depression 23%
Osteoporosis 21%
COPD 20%
Chronic kidney disease 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Haegarda
  • CSL Behring $253
$253 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $183
  • Amgen Inc. $50
$233 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $222
$222 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $220
$220 — —
DUPIXENT
  • GENZYME CORPORATION $148
  • Regeneron Healthcare Solutions, Inc. $64
$212 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

393 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record